NICE now backs Xalkori for first-line NSCLC

In a final appraisal determination, the U.K.'s NICE now recommends use of Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) for untreated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). The European Commission approved Xalkori in November 2015 for the indication.

In draft guidance issued in May, NICE recommended against the drug's use on the grounds that it was not cost effective compared with standard of care, even at an undisclosed discount. NICE's new recommendation is contingent on the pharma providing the drug at a larger discount under a patient access scheme. ...